Ten-year EFS, RR, and TRM according to recipient, donor, and transplant characteristics: univariate analyses
| Variable . | EFS, % (95% CI) . | RR, % (95% CI) . | TRM, % (95% CI) . |
|---|---|---|---|
| Age at transplant | |||
| Children | 54 (49-60) | 24 (20-29) | 22 (18-27) |
| Adolescents | 54 (41-67) | 23 (15-36) | 23 (14-36) |
| P | N.S. | N.S. | N.S. |
| Sex | |||
| Male | 49 (42-55) | 26 (22-33) | 25 (20-31) |
| Female | 65 (57-73) | 19 (13-27) | 16 (11-24) |
| P | 0.0051 | N.S. | 0.059 |
| Immunophenotype | |||
| B lineage | 55 (49-61) | 23 (18-28) | 22 (18-28) |
| T lineage | 47 (31-63) | 28 (16-47) | 25 (14-44) |
| P | N.S. | N.S. | N.S. |
| BFM class at relapse | |||
| S1 + S2 | 63 (55-70) | 17 (12-24) | 20 (15-27) |
| S3 + S4 | 38 (28-47) | 37 (29-47) | 26 (19-35) |
| Unknown | 58 (48-68) | 21 (15-30) | 21 (14-31) |
| P | < 0.0001 | 0.0002 | N.S. |
| Year of HSCT, all pts | |||
| Before 2000 | 49 (41-56) | 28 (22-36) | 23 (18-31) |
| 2000 or later | 58 (51-65) | 21 (16-27) | 21 (16-27) |
| P | 0.046 | 0.083 | N.S. |
| Year of HSCT, MFD | |||
| Before 2000 | 55 (46-64) | 30 (23-39) | 15 (10-23) |
| 2000 or later | 65 (53-76) | 20 (13-31) | 15 (8-27) |
| P | N.S. | N.S. | N.S. |
| Year of HSCT, UD | |||
| Before 2000 | 35 (22-48) | 24 (15-39) | 41 (30-56) |
| 2000 or later | 55 (46-63) | 21 (15-30) | 24 (18-32) |
| P | 0.0072 | N.S. | < 0.0001 |
| Donor | |||
| MFD | 59 (52-66) | 26 (20-33) | 15 (11-21) |
| UD | 50 (42-57) | 22 (17-29) | 29 (23-36) |
| P | 0.022 | N.S. | 0.0006 |
| HLA typing resolution | |||
| MFD | 59 (52-66) | 26 (20-33) | 15 (11-21) |
| HR UD | 57 (48-65) | 21 (15-29) | 22 (16-31) |
| LR UD | 35 (23-47) | 23 (14-36) | 42 (31-56) |
| P | 0.0003 | N.S. | < 0.0001 |
| Conditioning regimen | |||
| TBI + CHT | 56 (51-61) | 23 (19-27) | 22 (18-26) |
| CHT alone | 44 (27-60) | 31 (19-50) | 26 (15-45) |
| P | N.S. | 0.011 | N.S. |
| Infused nucleated cells | |||
| < 4 × 108/kg | 57 (49-64) | 22 (17-29) | 21 (16-28) |
| ≥ 4 × 108/Kg | 57 (49-64) | 26 (20-33) | 18 (13-25) |
| P | N.S. | N.S. | 0.0009 |
| aGvHD grade | |||
| 0 | 15 (1-28) | 67 (51-87) | 19 (8-41) |
| I | 66 (57-75) | 23 (16-32) | 11 (7-19) |
| II | 64 (56-73) | 20 (14-29) | 15 (10-23) |
| III | 58 (40-75) | 16 (7-36) | 27 (15-47) |
| IV | 14 (1-27) | 4 (1-24) | 82 (69-98) |
| P | < 0.0001 | < 0.0001 | < 0.0001 |
| cGvHD | |||
| Absent | 66 (59-72) | 28 (23-35) | 6 (4-11) |
| Limited | 76 (66-87) | 12 (6-23) | 11 (6-23) |
| Extensive | 57 (41-73) | 22 (12-40) | 21 (11-39) |
| P | N.S. | 0.054 | < 0.0001 |
| Variable . | EFS, % (95% CI) . | RR, % (95% CI) . | TRM, % (95% CI) . |
|---|---|---|---|
| Age at transplant | |||
| Children | 54 (49-60) | 24 (20-29) | 22 (18-27) |
| Adolescents | 54 (41-67) | 23 (15-36) | 23 (14-36) |
| P | N.S. | N.S. | N.S. |
| Sex | |||
| Male | 49 (42-55) | 26 (22-33) | 25 (20-31) |
| Female | 65 (57-73) | 19 (13-27) | 16 (11-24) |
| P | 0.0051 | N.S. | 0.059 |
| Immunophenotype | |||
| B lineage | 55 (49-61) | 23 (18-28) | 22 (18-28) |
| T lineage | 47 (31-63) | 28 (16-47) | 25 (14-44) |
| P | N.S. | N.S. | N.S. |
| BFM class at relapse | |||
| S1 + S2 | 63 (55-70) | 17 (12-24) | 20 (15-27) |
| S3 + S4 | 38 (28-47) | 37 (29-47) | 26 (19-35) |
| Unknown | 58 (48-68) | 21 (15-30) | 21 (14-31) |
| P | < 0.0001 | 0.0002 | N.S. |
| Year of HSCT, all pts | |||
| Before 2000 | 49 (41-56) | 28 (22-36) | 23 (18-31) |
| 2000 or later | 58 (51-65) | 21 (16-27) | 21 (16-27) |
| P | 0.046 | 0.083 | N.S. |
| Year of HSCT, MFD | |||
| Before 2000 | 55 (46-64) | 30 (23-39) | 15 (10-23) |
| 2000 or later | 65 (53-76) | 20 (13-31) | 15 (8-27) |
| P | N.S. | N.S. | N.S. |
| Year of HSCT, UD | |||
| Before 2000 | 35 (22-48) | 24 (15-39) | 41 (30-56) |
| 2000 or later | 55 (46-63) | 21 (15-30) | 24 (18-32) |
| P | 0.0072 | N.S. | < 0.0001 |
| Donor | |||
| MFD | 59 (52-66) | 26 (20-33) | 15 (11-21) |
| UD | 50 (42-57) | 22 (17-29) | 29 (23-36) |
| P | 0.022 | N.S. | 0.0006 |
| HLA typing resolution | |||
| MFD | 59 (52-66) | 26 (20-33) | 15 (11-21) |
| HR UD | 57 (48-65) | 21 (15-29) | 22 (16-31) |
| LR UD | 35 (23-47) | 23 (14-36) | 42 (31-56) |
| P | 0.0003 | N.S. | < 0.0001 |
| Conditioning regimen | |||
| TBI + CHT | 56 (51-61) | 23 (19-27) | 22 (18-26) |
| CHT alone | 44 (27-60) | 31 (19-50) | 26 (15-45) |
| P | N.S. | 0.011 | N.S. |
| Infused nucleated cells | |||
| < 4 × 108/kg | 57 (49-64) | 22 (17-29) | 21 (16-28) |
| ≥ 4 × 108/Kg | 57 (49-64) | 26 (20-33) | 18 (13-25) |
| P | N.S. | N.S. | 0.0009 |
| aGvHD grade | |||
| 0 | 15 (1-28) | 67 (51-87) | 19 (8-41) |
| I | 66 (57-75) | 23 (16-32) | 11 (7-19) |
| II | 64 (56-73) | 20 (14-29) | 15 (10-23) |
| III | 58 (40-75) | 16 (7-36) | 27 (15-47) |
| IV | 14 (1-27) | 4 (1-24) | 82 (69-98) |
| P | < 0.0001 | < 0.0001 | < 0.0001 |
| cGvHD | |||
| Absent | 66 (59-72) | 28 (23-35) | 6 (4-11) |
| Limited | 76 (66-87) | 12 (6-23) | 11 (6-23) |
| Extensive | 57 (41-73) | 22 (12-40) | 21 (11-39) |
| P | N.S. | 0.054 | < 0.0001 |
The log-rank test was used for comparisons of EFS probabilities, whereas the Gray test was used to compare cumulative incidences of relapse and TRM.
HR indicates high-resolution HLA typing (4 digits) for both first- and second-class HLA antigens; LR, low-resolution HLA typing (2 digits) for first-class HLA antigens and high-resolution HLA typing (4 digits) for second-class HLA antigens; CHT, chemotherapy; and N.S., not significant.